Sionna Therapeutics Takes Over Key Cystic Fibrosis Treatments From AbbVie
Sionna Therapeutics licenses CF treatments from AbbVie, including galicaftor and navocaftor.
Sionna Therapeutics, headquartered in Boston, USA, revealed today that it has secured exclusive global rights to develop and market several clinical-stage compounds under a new licensing agreement with pharmaceutical giant AbbVie (NYSE: ABBV). Founded in 2019, Sionna Therapeutics is a clinical-stage life sciences company focused on creating innovative and unique treatments for cystic fibrosis (CF). The company was established with a substantial $111 million Series B financing. As part of the agreement with AbbVie, Sionna will take over the development of three cystic fibrosis treatments: galicaftor, a TMD1-targeted CFTR corrector; navocaftor, a CFTR potentiator; and ABBV-2851, a Phase 1 TMD1-targeted corrector. Both galicaftor and navocaftor have successfully completed Phase II trials.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion